Here's what the grant actually represents: not a new discovery so much as the continued extension of a foundational estate that much of the gene-editing industry has to reckon with.
Strip away the decade-old drama about who invented CRISPR first, and the practical reality is simpler. The Broad Institute holds a deep set of patents on the core editing enzymes and systems. Its 2022 grant US11352647B2 on CRISPR enzymes and systems is one more brick in that wall.
Why does a single grant to one institute ripple outward? Because gene-editing therapies are built on these enzymes. A company developing a CRISPR treatment for a disease often finds that the basic machinery it depends on touches foundational claims — which means licensing, or designing around them.
You can see the design-around pressure in the same year's filings. Rutgers' US11390886B2 describes a nuclease-independent editing platform — an approach that deliberately steps off the most heavily claimed ground. Inventors don't pursue alternatives in a vacuum; they do it partly to find freedom to operate.
The crosswalk worth keeping: a foundational patent isn't just a credit line on a discovery — it's a tollbooth on a road the whole field drives. When the Broad issues another core grant, it's reinforcing that tollbooth, and that's a commercial fact every gene-editing company has to plan around.
None of this resolves who 'deserves' the credit, and a pending or issued claim isn't the last word in a contested area. But for a reader trying to understand why CRISPR economics are so tangled, the answer starts here: the foundational estate is active, broad, and still growing.